Display Settings:

Format

Send to:

Choose Destination
J Glob Infect Dis. 2010 May;2(2):167-76. doi: 10.4103/0974-777X.62887.

Drug resistance in leishmaniasis.

Author information

  • 1Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi-221 005, India.

Abstract

The treatment options of leishmaniasis are limited and far from satisfactory. For more than 60 years, treatment of leishmaniasis has centered around pentavalent antimonials (Sb(v)). Widespread misuse has led to the emergence of Sb(v) resistance in the hyperendemic areas of North Bihar. Other antileishmanials could also face the same fate, especially in the anthroponotic cycle. The HIV/ visceral leishmaniasis (VL) coinfected patients are another potential source for the emergence of drug resistance. At present no molecular markers of resistance are available and the only reliable method for monitoring resistance of isolates is the technically demanding in vitro amastigote-macrophage model. As the armametrium of drugs for leishmaniasis is limited, it is important that effective monitoring of drug use and response should be done to prevent the spread of resistance. Regimens of simultaneous or sequential combinations should be seriously considered to limit the emergence of resistance.

KEYWORDS:

Antimony; Leishmaniasis; Resistance

PMID:
20606973
[PubMed]
PMCID:
PMC2889657
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
    Loading ...
    Write to the Help Desk